Mark Blumling

Mark Blumling serves as an Executive Advisor at New Mountain Capital, focusing on sourcing and evaluating investment opportunities in life sciences and healthcare for a substantial fund. In addition, Mark holds a position as a Lecturer at Stanford Law School, where the course 'Creating Value: Private Equity, Venture Capital and Entrepreneurism' was developed and is being taught. As a member of YPO, a global organization for chief executives, and a Life Member at the Council on Foreign Relations, Mark engages in leadership and policy discussions. Previously, Mark founded and led Headlands Research, a prominent multi-therapeutic clinical trial site organization, which was financially backed by KKR and acquired by THL. Mark holds a BA in Human Biology from Stanford University and a JD from Stanford Law School.